戻る Agenda
PMDA Townhall
Session Chair(s)
Daisuke Tanaka, PHD
Office Director, Office of International Programs
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
- Introduction of the PMDA’s plan and the direction to achieve, with the essence of its new 5-year mid-term plan scheduled from FY2024 - Clearing up misconceptions that have become bad urban legends about Japan when companies are considering R&D on new medicines in Japan - The attractiveness of performing R&D in Japan will be presented and clarified through discussions from the regulatory and industrial perspectives.
Learning Objective : 1. To recognize latest information on the Pharmaceuticals and Medical Devices Agency’s activity and Japanese regulations in medical products area. 2. To discuss issues on medical products regulation with senior PMDA officials
Speaker(s)
Future Vision of PMDA - 5th Mid-Term Plan
Shinobu Uzu, PHD
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Senior Executive Director
Major Initiatives for Promoting Drug Development in Japan
Kenichi Tamiya, MSC, RPH
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Associate Executive Director, Office of New Drug
Industry Perspective for Drug Development in Japan
Atsushi Tsukamoto, PHD, MSC
Daiichi Sankyo, United States
Head is Therapeutic Area Strategies
Panelist
Yves Jacob
sanofi-aventis Recherche & Developpment, France
Head of Global Regulatory Affairs for Europe Region